A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Sponsor: BeiGene
About this study
This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (115)
| Carti Cancer Center | Little Rock, Arkansas, United States | — |
| David Geffen School of Medicine At UCLA | Los Angeles, California, United States | — |
| Rocky Mountain Cancer Centers Boulder | Boulder, Colorado, United States | — |
| Scri Florida Cancer Specialists South | Fort Myers, Florida, United States | — |
| Scri Florida Cancer Specialists North | St. Petersburg, Florida, United States | — |
| Augusta University | Augusta, Georgia, United States | — |
| Norton Cancer Institute Pavilion | Louisville, Kentucky, United States | — |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Forrest General Hospital Cancer Center | Hattiesburg, Mississippi, United States | — |
| Scri Hca Midwest Health | Kansas City, Missouri, United States | — |
| Nebraska Medical Center | Omaha, Nebraska, United States | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas, Nevada, United States | — |
+ 103 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03734016